Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
Purpose: The recurrent/progressive glioblastoma multiforme (GBM) carries a dismal prognosis and the definitive treatment strategy has not yet been established. This study aimed to assess the efficacy and safety of apatinib in recurrent/progressive GBM patients.Materials and methods: The clinical dat...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.969565/full |
| _version_ | 1798039847640760320 |
|---|---|
| author | Hong-Hong Zhang Hong-Hong Zhang Xiao-Jing Du Mei-Ling Deng Lie Zheng Dun-Chen Yao Zhi-Qiang Wang Qun-Ying Yang Shao-Xiong Wu |
| author_facet | Hong-Hong Zhang Hong-Hong Zhang Xiao-Jing Du Mei-Ling Deng Lie Zheng Dun-Chen Yao Zhi-Qiang Wang Qun-Ying Yang Shao-Xiong Wu |
| author_sort | Hong-Hong Zhang |
| collection | DOAJ |
| description | Purpose: The recurrent/progressive glioblastoma multiforme (GBM) carries a dismal prognosis and the definitive treatment strategy has not yet been established. This study aimed to assess the efficacy and safety of apatinib in recurrent/progressive GBM patients.Materials and methods: The clinical data of 19 recurrent/progressive GBM patients who received apatinib treatment from November 2015 to December 2019 at Sun Yat-sen University Cancer Center were collected retrospectively in this study. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (AEs) were reviewed and assessed.Results: The overall ORR was 52.6%, and the DCR was 73.7%. Median PFS and OS were 5.1 and 10.4 months, respectively. The 6-month PFS and OS rates were 38.9% and 68.4%, respectively. The 12-month PFS and OS rates were 16.7% and 36.8%, respectively. The treatment-related toxicities were generally well-tolerated. The most common grade 3/4 AEs were hand-foot syndrome (36.8%) and hypertension (21.1%).Conclusion: Our study showed that apatinib therapy provided a better salvaging option for recurrent/progressive GBM patients and the toxicity was manageable. |
| first_indexed | 2024-04-11T21:59:20Z |
| format | Article |
| id | doaj.art-39caa135a9d24098a43c03e4e09b8aed |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T21:59:20Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-39caa135a9d24098a43c03e4e09b8aed2022-12-22T04:01:00ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.969565969565Apatinib for recurrent/progressive glioblastoma multiforme: A salvage optionHong-Hong Zhang0Hong-Hong Zhang1Xiao-Jing Du2Mei-Ling Deng3Lie Zheng4Dun-Chen Yao5Zhi-Qiang Wang6Qun-Ying Yang7Shao-Xiong Wu8Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiation Oncology, Xiang’an Hospital of Xiamen University, Cancer Research Center, School of Medicine, Xiamen University, Xiamen, ChinaDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Medical Imaging, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Neurosurgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaPurpose: The recurrent/progressive glioblastoma multiforme (GBM) carries a dismal prognosis and the definitive treatment strategy has not yet been established. This study aimed to assess the efficacy and safety of apatinib in recurrent/progressive GBM patients.Materials and methods: The clinical data of 19 recurrent/progressive GBM patients who received apatinib treatment from November 2015 to December 2019 at Sun Yat-sen University Cancer Center were collected retrospectively in this study. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (AEs) were reviewed and assessed.Results: The overall ORR was 52.6%, and the DCR was 73.7%. Median PFS and OS were 5.1 and 10.4 months, respectively. The 6-month PFS and OS rates were 38.9% and 68.4%, respectively. The 12-month PFS and OS rates were 16.7% and 36.8%, respectively. The treatment-related toxicities were generally well-tolerated. The most common grade 3/4 AEs were hand-foot syndrome (36.8%) and hypertension (21.1%).Conclusion: Our study showed that apatinib therapy provided a better salvaging option for recurrent/progressive GBM patients and the toxicity was manageable.https://www.frontiersin.org/articles/10.3389/fphar.2022.969565/fullapatinibrecurrent/progressive glioblastoma multiformeefficacysafetyVEGFR |
| spellingShingle | Hong-Hong Zhang Hong-Hong Zhang Xiao-Jing Du Mei-Ling Deng Lie Zheng Dun-Chen Yao Zhi-Qiang Wang Qun-Ying Yang Shao-Xiong Wu Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option Frontiers in Pharmacology apatinib recurrent/progressive glioblastoma multiforme efficacy safety VEGFR |
| title | Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option |
| title_full | Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option |
| title_fullStr | Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option |
| title_full_unstemmed | Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option |
| title_short | Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option |
| title_sort | apatinib for recurrent progressive glioblastoma multiforme a salvage option |
| topic | apatinib recurrent/progressive glioblastoma multiforme efficacy safety VEGFR |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.969565/full |
| work_keys_str_mv | AT honghongzhang apatinibforrecurrentprogressiveglioblastomamultiformeasalvageoption AT honghongzhang apatinibforrecurrentprogressiveglioblastomamultiformeasalvageoption AT xiaojingdu apatinibforrecurrentprogressiveglioblastomamultiformeasalvageoption AT meilingdeng apatinibforrecurrentprogressiveglioblastomamultiformeasalvageoption AT liezheng apatinibforrecurrentprogressiveglioblastomamultiformeasalvageoption AT dunchenyao apatinibforrecurrentprogressiveglioblastomamultiformeasalvageoption AT zhiqiangwang apatinibforrecurrentprogressiveglioblastomamultiformeasalvageoption AT qunyingyang apatinibforrecurrentprogressiveglioblastomamultiformeasalvageoption AT shaoxiongwu apatinibforrecurrentprogressiveglioblastomamultiformeasalvageoption |